McGary C T, Yannariello-Brown J, Kim D W, Stinson T C, Weigel P H
Department of Human Biological Chemistry and Genetics, University of Texas Medical Branch, Galveston 77555-0647.
Hepatology. 1993 Dec;18(6):1465-76.
The release and intracellular accumulation of 125I-hyaluronan degradation products was studied in cultured liver endothelial cells with hyaluronan oligosaccharides (relative molecular mass = approximately 44,000) uniquely modified and radiolabeled at the terminal reducing sugar. Two methods were combined to measure 125I-hyaluronan degradation by liver endothelial cells. (a) Cetylpyridinium chloride precipitation of hyaluronan oligosaccharides was used as a rapid, convenient assay to monitor the appearance of hyaluronan degradation products. Hyaluronan oligosaccharides less than 54 to 60 monosaccharides in length were not precipitated with cetylpyridinium chloride and thus were assessed as degraded. (b) Gel filtration chromatography was used to estimate the size range of oligosaccharides produced by liver endothelial cells. After internalization of 125I-hyaluronan, liver endothelial cells released radioactive degradation products into the culture media after a lag period of 2.5 to 3.0 hr. The intracellular accumulation of degraded 125I-hyaluronan was linear for at least 2 hr even though no degradation products were released. The long lag before release of degraded 125I-hyaluronan is likely caused by the modified chemical structure at the reducing end of the hyaluronan derivative; the derivative acts like a residualizing label. After this lag the release of degraded 125I-hyaluronan proceeded linearly for up to 12 hr. The extracellular 125I-hyaluronan degradation products eluted with a distribution coefficient of 1.3 on a gel filtration column. The major intracellular 125I-labeled degradation product showed the same retardation (distribution coefficient = 1.3). This retention may be caused by the hydrophobic aromatic and alkyl modifications to the former reducing sugar, also characteristics of a residualizing label. In addition, at least two larger minor intermediates were observed intracellularly. The rate of intracellular 125I-hyaluronan degradation was dependent on hyaluronan concentration and reached a maximal rate (159 molecules/cell/sec) at 2 x 10(-7) mol/L. This was about half the maximal rate of endocytosis (285 molecules/cell/sec) at a hyaluronan concentration of 1.3 x 10(-7) mol/L. The apparent ligand concentration that gives half-maximal responses for endocytosis and intracellular degradation was 0.6 x 10(-7) and 1.0 x 10(-7) mol/L, respectively.
在培养的肝内皮细胞中,研究了125I-透明质酸降解产物的释放和细胞内积累情况,所用的透明质酸寡糖(相对分子质量约为44,000)在末端还原糖处经过独特修饰并进行了放射性标记。采用两种方法相结合来测定肝内皮细胞对125I-透明质酸的降解。(a) 用十六烷基吡啶氯化物沉淀透明质酸寡糖作为一种快速、便捷的检测方法,以监测透明质酸降解产物的出现。长度小于54至60个单糖的透明质酸寡糖不会被十六烷基吡啶氯化物沉淀,因此被视为已降解。(b) 凝胶过滤色谱法用于估计肝内皮细胞产生的寡糖的大小范围。125I-透明质酸内化后,肝内皮细胞在2.5至3.0小时的延迟期后将放射性降解产物释放到培养基中。即使没有释放降解产物,降解的125I-透明质酸在细胞内的积累至少2小时呈线性。降解的125I-透明质酸释放前的长时间延迟可能是由透明质酸衍生物还原端的化学结构修饰引起的;该衍生物起到残留标记的作用。在此延迟之后,降解的125I-透明质酸的释放持续长达12小时呈线性。细胞外的125I-透明质酸降解产物在凝胶过滤柱上以分配系数1.3洗脱。主要的细胞内125I标记降解产物显示出相同的滞留情况(分配系数 = 1.3)。这种滞留可能是由对先前还原糖的疏水芳香族和烷基修饰引起的,这也是残留标记的特征。此外,在细胞内观察到至少两种更大的次要中间体。细胞内125I-透明质酸的降解速率取决于透明质酸浓度,在2×10(-7) mol/L时达到最大速率(159个分子/细胞/秒)。这约为透明质酸浓度为1.3×10(-7) mol/L时内吞作用最大速率(285个分子/细胞/秒)的一半。内吞作用和细胞内降解产生半最大反应的表观配体浓度分别为0.6×10(-7) 和1.0×10(-7) mol/L。